


Challenges to Increase Access to Vaccines in the Americas


Dr. Jarbas Barbosa
Assistant Director
Pan American Health Organization

The Region: Good news

The path of disease elimination



Number of unvaccinated children with DPT3 per year, selected countries and Region, 2010- 2018




Source: PAHO-WHO/UNICEF 2019 joint reporting form (JRF) on immunization (2018 data).

Antigens introduced in national immunization schedules

**Rotavirus:
22 countries
and territories**

Legend


- Introduced
- Partial
- Haven't introduced



**PCV:
37 countries
and territories**

Legend

- Introduced
- Haven't introduced



The Region: Challenges



Rapid Urbanization

80%

56 (2010)



Natural disasters

6.6 quake hits Mexico;

Peru: Deadly floods and landslides hit Huancavelica

Deadly landslides hit Colombia for 2nd time in 2 weeks

Saint Martin Is Making a Comeback After Hurricane Irma

Guatemala's erupting Volcan de Fuego triggers evacuations



Political context

Qué es el 'caso Odebrecht' y cómo afecta a cada país de América Latina

EL PAÍS

Deaths reported as protests against President turn violent



The New York Times ES

Nueve vicios de las elecciones latinoamericanas en un solo ejemplo



reportan nuevo apagón masivo



¿Se muere el sueño de la paz?



Equity

CEPAL: Pese a avances recientes, América Latina sigue siendo la región más desigual del mundo

<https://www.cepal.org/es/publicaciones/44395-panorama-social-america-latina-2018>

Key Components for Access to Vaccines

Accurate demand planning



Timely availability of funds



Efficient procurement mechanisms



Sustainable/affordable supply market



ACCESS



The PAHO Revolving Fund

41 countries
and territories

25 million


people are protected annually with at least
one vaccine procured through
the PAHO Revolving Fund



A Snapshot of Developing Country Manufacturers



PAHO/WHO's Program of **Technical Cooperation** for National Immunization Programs: Evidence-based Decision Making



Source: Andrus, JK., Toscano, CM., Lewis, M., Oliveira, L., et al. 2007, "A model for enhancing evidence-based capacity to make informed policy decisions on the introduction of new vaccines in the Americas: PAHO's ProVac Initiative", *Public Health Reports*, 122(6): 811-816.

Strengthening Vaccine Production Capacities for National Laboratories, 2019

Update to landscape analysis - Diagnosis

of existing manufacturing capabilities, national products, plans processes and alliances.

Identifying opportunities for interaction

with laboratories
Impacting their production plans and procedures

Outline broader PAHO strategy

to ensure commitments compliance and regional solidarity

Based on principles of transparency, avoid conflicts of interest while proposing a corporate strategy for consideration

Challenges for the supply

- Stagnant/decreasing coverage rates
- Global supply constraints for critical vaccines like IPV, Measles Containing Vaccines, Yellow Fever, HPV
- Concentrated (monopolistic) supply market for some products
- High prices for new vaccines
- Forecasting accuracy, programme planning and stock management
- Suboptimal production capacities and product portfolio for the national manufacturers in the Latin America

PAHO's involvement over the years to support national production capacities



PAHO has been providing guidance for increasing technical and regulatory capacities. There are selected publications by PAHO experts.

The PAHO Executive Committee Meeting in 1994 called on Member Countries for the promotion of vaccine production, including public and private producing laboratories (SIREVA).


Implementation of strategies for DTP manufacturing improvement, Penta Latina development, etc.

Promotion of partnering for vaccine emerging markets and attention to vaccine demand and chain supply.

Encouraging South-South cooperation.



PAHO RF's Evolving Vaccine Market Trends: Role of IFPMA* and DCVMN** Suppliers, 2011-18



Additional saving as result of buying from DCVMN (Ex. Penta \$3.50 - \$1.00)

Result from negotiations with two HPV suppliers: US\$1.5 millions in savings⁺

Result from negotiations with two PCV suppliers: US\$10.9 millions in savings⁺⁺

⁺ For participating countries from 2017-2018

⁺⁺ For participating countries from 2017-2018

* IFPMA: International Federation of Pharmaceutical Manufacturers

** DCVMN: Developing Countries Vaccine Manufacturers Network

Way Forward

1. Enhanced coordination on **Demand Planning**
 - Forecasting accuracy
 - Outbreak risk / scenario analysis
 - Joint demand planning with self-procuring countries
2. Technical Support to **National Regulatory Authorities**
3. Technical Support to national manufacturing capacities
 - Diagnostic on capacities
 - South-south collaboration
 - Promoting public-private partnerships and sustainable business models
4. Strengthening collaborations with international partners on vaccine access
 - WHO's EYE initiative
 - Measles Rubella Initiative (MRI)
 - GPEI



Thank you!